Phase 1 Clinical Trial Demonstrated That MUC1 Positive Metastatic Seminal Vesicle Cancer Can Be Effectively Eradicated by Modified Anti-Muc1 Chimeric Antigen Receptor Transduced T Cells
Science China Life Sciences - China
doi 10.1007/s11427-016-5024-7
Full Text
Open PDFAbstract
Available in full text
Date
March 7, 2016
Authors
Publisher
Springer Science and Business Media LLC